TCR2 Therapeutics to Announce Extended Results from Ongoing Phase 1/2 Trial of Gavo-cel in Mesothelin-Expressing Solid Tumors
September 13 2021 - 6:45AM
TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell
therapy company with a pipeline of novel T cell therapies for
patients suffering from cancer, today announced that the Company
will host a conference call and live audio webcast on Friday,
September 17, 2021 at 9:00am E.T. to discuss extended data from the
ongoing Phase 1 portion of the gavo-cel Phase 1/2 clinical trial
for mesothelin-expressing solid tumors.
The dataset will be an extension of the oral
presentation at the European Society for Medical Oncology (ESMO)
Congress 2021 on September 17 at 14:20 CEST (8:20am ET)
(Presentation #959O) that is part of the official ESMO Press
Programme. The Company presentation will include clinical and
translational data from at least 17 evaluable patients with
gavo-cel up to dose level 5 (DL5) in three mesothelin-expressing
solid tumor indications: malignant mesothelioma, ovarian cancer and
cholangiocarcinoma.
In order to participate in the conference call,
please dial 866-220-8062 (domestic) or 470-495-9169 (international)
and refer to confirmation number 1597681. The webcast and
presentation will be made available on the TCR2 Therapeutics
website in the Investors section under Events at
investors.tcr2.com/events. Following the live audio webcast, a
replay will be available on the Company's website for approximately
30 days.
About TCR2
Therapeutics
TCR2 Therapeutics Inc. is a
clinical-stage cell therapy company developing a pipeline of novel
T cell therapies for patients suffering from
cancer. TCR2’s proprietary T cell receptor (TCR) Fusion
Construct T cells (TRuC®-T cells) specifically recognize and
kill cancer cells by harnessing signaling from the entire TCR,
independent of human leukocyte antigens (HLA). In preclinical
studies, TRuC-T cells have demonstrated superior anti-tumor
activity compared to chimeric antigen receptor T cells (CAR-T
cells), while secreting lower levels of cytokine release. The
Company’s lead TRuC-T cell product candidate targeting solid
tumors, gavo-cel, is currently being studied in a Phase 1/2
clinical trial to treat patients with mesothelin-positive non-small
cell lung cancer (NSCLC), ovarian cancer, malignant
pleural/peritoneal mesothelioma, and cholangiocarcinoma. The
Company’s lead TRuC-T cell product candidate targeting
hematological malignancies, TC-110, is currently being studied in a
Phase 1/2 clinical trial to treat patients with CD19-positive adult
acute lymphoblastic leukemia (aALL) and with aggressive or indolent
non-Hodgkin lymphoma (NHL). For more information about TCR2, please
visit www.tcr2.com.
Investor and Media Contact:
Carl MauchDirector, Investor Relations and
Corporate CommunicationsTCR2 Therapeutics Inc.(617)
949-5667carl.mauch@tcr2.com
TCR2 Therapeutics (NASDAQ:TCRR)
Historical Stock Chart
From Mar 2024 to Apr 2024
TCR2 Therapeutics (NASDAQ:TCRR)
Historical Stock Chart
From Apr 2023 to Apr 2024